Breaking Business News | Breaking business news AM | Breaking Business News PM

A new batch of data for Gilead Sciences’ remdesivir points to efficacy but it’s no ‘silver bullet’

2 Jun 2020

A slice of data from the third clinical trial for Gilead Sciences Inc.’s remdesivir indicates that the experimental therapy is somewhat effective in treating COVID-19 patients but is not the silver bullet that had been hoped for.


Read the full article here.
This content was originally published by MarketWatch.com - Top Stories. Original publishers retain all rights. It appears here for a limited time before automated archiving. By MarketWatch.com - Top Stories

Covid-19 – Johns Hopkins University

Download brochure

Introduction brochure

What we do, case studies and profiles of some of our amazing team.

Download